SCHEMBL420688

SCHEMBL420688

COC(=O)c1cc(Cl)ccc1NC(=O)c1ccccc1-c1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 1/20 0.62
SLC6A3 Q01959 1/20 0.62
ALDH1A1 P00352 4/20 0.55
MAPT P10636 4/20 0.54
SERPINE1 P05121 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
NPC1 O15118 1/20 0.54
HPGD P15428 1/20 0.54
LMNA P02545 2/20 0.53
HTT P42858 3/20 0.52
GAA P10253 2/20 0.52
POLB P06746 1/20 0.52
KDM4E B2RXH2 3/20 0.52
CHRNB2 P17787 2/20 0.51
CHRNB4 P30926 2/20 0.51
CHRNA3 P32297 2/20 0.51
CHRNA4 P43681 2/20 0.51
TP53 P04637 1/20 0.51
NPSR1 Q6W5P4 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL418103 0.87 SERPINE1 (0.71) ALDH1A1MAPTSERPINE1LMNAHTT
SCHEMBL896770 0.83 ALDH1A1 (0.69) SLC6A4SLC6A3ALDH1A1MAPTSMN1; SMN2
SCHEMBL420185 0.82 SERPINE1 (0.77) ALDH1A1MAPTSERPINE1SMN1; SMN2NPC1
SCHEMBL420252 0.82 HPGD (0.72) ALDH1A1MAPTSMN1; SMN2HPGDLMNA
SCHEMBL7040693 0.81 PPARG (0.60) ALDH1A1MAPTSERPINE1LMNAKDM4E
SCHEMBL419651 0.81 HPGD (0.74) ALDH1A1MAPTSERPINE1SMN1; SMN2NPC1
SCHEMBL7038586 0.80 PPARG (0.61) ALDH1A1SERPINE1SMN1; SMN2NPC1HPGD
SCHEMBL417240 0.79 HSP90AA1 (0.50) SLC6A4SLC6A3ALDH1A1MAPTSMN1; SMN2
SCHEMBL5234812 0.79 GAA (0.61) SLC6A4SLC6A3ALDH1A1MAPTSMN1; SMN2
SCHEMBL896973 0.79 F10 (0.56) SLC6A4SLC6A3ALDH1A1SERPINE1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2607348-B1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE INC (JP) 2021-03-17 EP disclosed
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO LTD (JP) 2014-10-02 US disclosed
US-8785473-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2014-07-22 US disclosed
EP-2607348-A2 Plasminogen Activator Inhibitor-1 Inhibitor Renascience CO., LTD. (JP) 2013-06-26 EP disclosed
EP-2415755-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Renascience CO., LTD. (JP) 2012-02-08 EP disclosed
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE CO., LTD. (JP) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 SLC6A4 4798/4885SLC6A3 4863/4885ALDH1A1 1450/4885
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 SLC6A4 4798/4885SLC6A3 4863/4885ALDH1A1 1450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.